logo-loader
viewOpen Orphan PLC

Open Orphan: World-leading expertise drives growth

Open Orphan (LON:ORPH) has rapidly restructured and integrated its Venn and hVIVO subsidiaries, and is delivering on its growth strategy by maximising its specialist capabilities and is converting a pipeline with an estimated value of over £100mln, to deliver long-term, profitable contracts.

This was highlighted by a recent win with a top-three global pharma company to deliver a respiratory syncytial virus (RSV) human challenge study clinical trial, reinforcing its world-leading position in the space. ORPH is also driving forward its strategy via expanding hVIVO lab services to third-parties and has signed a series of new contracts with antiviral, vaccine and respiratory therapeutic developers, including a COVID-19 vaccine testing contract with Codagenix.


 

 


 

Quick facts: Open Orphan PLC

Price: 18.75 GBX

AIM:ORPH
Market: AIM
Market Cap: £124.8 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

on 10/8/20

5 min read